PDCD1 and neuropathy: In examining race and ethnicity of the patients who had documented neuropathy associated with PD-1 inhibitor exposure, those who self-identified as “Other” race had a higher prevalence when compared to White or Caucasian patients (Table 1; OR 1.514, 95% CI 1.071–2.140, p = 0.0189) and those who identified as non-Hispanic or Latino had higher number of documented neuropathies associated with PD-1 inhibitor exposure when compared to Hispanic or Latino patients (Table 1; OR 1.502, 95% CI 1.113–2.028, p = 0.0078).